INDEPENDENT THINKING. WHOLE-FOOD LIVING.NO ANIMALS / NO OIL
THENANODIET
← THE STUDY LIBRARY

Clinical trial / 2005

Urtica dioica improved symptoms, urinary flow rates, and residual volume, and modestly reduced prostate size in men with benign prostatic hyperplasia.

A 6-month randomized, double-blind, placebo-controlled trial with a partial crossover evaluated Urtica dioica versus placebo in 620 patients with benign prostatic hyperplasia, followed up to 18 months. At 6 months, 81% (232/287) of patients in the Urtica dioica group reported improved symptoms compared with 16% (43/271) receiving placebo (P < 0.001). IPSS decreased from 19.8 to 11.8 with Urtica dioica versus 19.2 to 17.7 with placebo (P = 0.002), while peak flow rates improved by 8.2 mL/s versus 3.4 mL/s (P < 0.05). Postvoid residual volume decreased from 73 to 36 mL (P < 0.05) and prostate size decreased modestly from 40.1 to 36.3 cc (P < 0.001) with Urtica dioica, without changes in PSA or testosterone and with no identified side effects.

Study type
Randomized, double-blind, placebo-controlled, partial crossover trial
Who was studied
620 patients with lower urinary tract symptoms secondary to benign prostatic hyperplasia
What was measured
IPSS, Qmax, postvoid residual urine volume, serum PSA, testosterone, and prostate size

THE PAPER

Urtica dioica for treatment of benign prostatic hyperplasia: a prospective, randomized, double-blind, placebo-controlled, crossover study.

Safarinejad MR. J Herb Pharmacother, 2005.

PubMed 16635963 ↗

Other health

This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.